Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.5.2.3 extracted from

  • Schroeder, P.E.; Davidson, J.N.; Hasinoff, B.B.
    Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187) (2002), Drug Metab. Dispos., 30, 1431-1435.
    View publication on PubMed
Search for more literature for 3.5.2.3

Application

Application Comment Organism
medicine activation of the cardioprotective agent dexrazoxane by the enzyme in heart, mechanism Mesocricetus auratus

Inhibitors

Inhibitors Comment Organism Structure
5-aminoorotate 1 mM, 90% inhibition Mesocricetus auratus
Furosemide 1 mM, 80% inhibition Mesocricetus auratus
additional information not inhibitory: 4-chlorobenzenesulfonamide Mesocricetus auratus

KM Value [mM]

KM Value [mM] KM Value Maximum [mM] Substrate Comment Organism Structure
0.02
-
 (S)-dihydroorotate pH 7.4, 15Ā°C Mesocricetus auratus

Organism

Organism UniProt Comment Textmining
Mesocricetus auratus
-
-
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
(S)-dihydroorotate + H2O
-
 Mesocricetus auratus N-carbamoyl-L-aspartate
-
 ?
dexrazoxane + H2O i.e. ICRF187 or (+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane, cardioprotective agent Mesocricetus auratus ADR-925 i.e. N,NĀ’-[(1S)-1-methyl-1,2-ethanediyl]bis[N-(2-amino-2-oxoethyl)glycine], biologically active form ?